	US 11,723,899 B2
	ALK2 inhibitors for the treatment of anemia
Francis Séguy, Lausanne (CH); Ekaterine Asatiani, Founex (CH); and Yaoyu Chen, Newark, DE (US)
Assigned to INCYTE CORPORATION, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Jun. 15, 2021, as Appl. No. 17/348,102.
Claims priority of provisional application 63/152,516, filed on Feb. 23, 2021.
Claims priority of provisional application 63/056,761, filed on Jul. 27, 2020.
Claims priority of provisional application 63/039,742, filed on Jun. 16, 2020.
Prior Publication US 2021/0393605 A1, Dec. 23, 2021
Int. Cl. A61K 31/4439 (2006.01); A61P 7/06 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/4439 (2013.01) [A61K 9/0053 (2013.01); A61P 7/06 (2018.01)]

25 Claims

1. A method of treating anemia in a subject in need thereof, comprising administering to the subject a compound that is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide, or a pharmaceutically acceptable salt thereof.